Thomas Ferguson
Fiona Stanley Hospital · 27 works · 2,047 citations · h-index 12
Top works
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
- Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- Taxanes for adjuvant treatment of early breast cancer
- Pembrolizumab plus lenvatinib as first-line therapy for advanced non-clear-cell renal cell carcinoma (KEYNOTE-B61): a single-arm, multicentre, phase 2 trial
- Taxanes for adjuvant treatment of early breast cancer
- Assessment of the contribution of the IHC4+C score to decision making in clinical practice in early breast cancer
- First-line Systemic Therapy Following Adjuvant Immunotherapy in Renal Cell Carcinoma: An International Multicenter Study
- Patient-Reported Outcomes in KEYNOTE-564: Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma
- Overall survival results from the phase 3 KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for the treatment of clear cell renal cell carcinoma (ccRCC).
- The SUB ‐urothelial DUrvalumab InjEction ‐1 ( SUBDUE ‐1) trial: first‐in‐human trial in patients with bladder cancer
- Adjuvant pembrolizumab plus belzutifan versus pembrolizumab for clear cell renal cell carcinoma (ccRCC): The randomized phase 3 LITESPARK-022 study.
- 653O Pembrolizumab (pembro) vs placebo as adjuvant therapy for patients (pts) with renal cell carcinoma (RCC): Patient-reported outcomes (PRO) in KEYNOTE-564
- First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
- First-line pembrolizumab plus lenvatinib for non–clear cell renal carcinomas (nccRCC): Extended follow-up of the phase 2 KEYNOTE-B61 study.
- Bisphosphonates for prevention of bone loss in women with early breast cancer
- Bisphosphonates for prevention of bone loss in women with early breast cancer
- A meta-analysis of taxanes in adjuvant chemotherapy (ACT) of early breast cancer (EBC)
- First-line lenvatinib + pembrolizumab treatment across non-clear cell renal cell carcinomas: Results of the phase 2 KEYNOTE-B61 study.
- Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Insights from the Western Australian Context
- 1Pembrolizumab plus lenvatinib for previously untreated advanced non–clear cell renal cell carcinoma: 3-year follow-up of the phase 2 KEYNOTE-B61 study